Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

CG Oncology, Inc. Common stock

Healthcare US CGON

65.73USD
-0.52(0.78%)

Last update at 2026-06-23T20:01:00Z

Day Range

63.7566.69
LowHigh

52 Week Range

20.5373.56
LowHigh

Fundamentals

  • Previous Close 66.25
  • Market Cap6065.82M
  • Volume846391
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-189.32899M
  • Revenue TTM4.04M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM -117.24800M
  • Diluted EPS TTM-2.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -160.99500M -88.03900M -48.60700M -35.44300M -12.83900M
Minority interest - - - - -
Net income -160.99500M -88.03900M -48.60700M -35.44300M -12.83900M
Selling general administrative 73.53M 33.70M 9.90M 6.41M 4.64M
Selling and marketing expenses - - - - -
Gross profit -0.60700M 1.14M - - -
Reconciled depreciation 1.45M 0.03M 0.02M 0.01M 0.01000M
Ebit -160.99500M -114.66600M - - -
Ebitda -159.55000M -114.63400M - - -
Depreciation and amortization 1.45M 0.03M - - -
Non operating income net other - - - - -
Operating income -190.77400M -114.66600M -55.44900M -35.24600M -12.60600M
Other operating expenses 194.81M 115.81M - - -
Interest expense - - - 0.00100M 0.45M
Tax provision - - - - -
Interest income 29.93M 26.62M - - -
Net interest income 29.93M 26.62M 6.90M -0.00100M -0.45100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 4.04M 1.14M 0.20M 0.19M 10.36M
Total operating expenses 190.17M 115.81M 55.65M 35.44M 22.96M
Cost of revenue 4.65M 0.03M - - -
Total other income expense net 29.78M 26.63M -0.06200M -0.19600M 0.22M
Discontinued operations - - - - -
Net income from continuing ops -160.99500M -88.03900M -48.60700M -35.44300M -12.83900M
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 791.59M 754.80M 199.30M 147.75M 58.69M
Intangible assets 0.57M - - - -
Earning assets - - - - -
Other current assets 15.07M 11.43M 6.36M 3.42M 4.80M
Total liab 38.99M 21.42M 14.51M 22.57M 101.31M
Total stockholder equity 752.60M 733.38M 184.79M 125.18M -42.61800M
Deferred long term liab - - - - -
Other current liab 24.21M 14.66M 0.45M 0.17M 0.07M
Common stock 0.00800M 0.00800M - - -
Capital stock 0.00800M 0.00800M 307.89M 202.87M 0.00000M
Retained earnings -378.97600M -217.98100M -129.94200M -81.33500M -45.89200M
Other liab - - - - -
Good will 10.30M - - - -
Other assets - - - - -
Cash 32.49M 257.07M 8.27M 88.14M 53.61M
Cash and equivalents - - - - -
Total current liabilities 30.84M 21.37M 14.25M 15.43M 5.97M
Current deferred revenue - - - - -
Net debt -25.46900M -256.83000M - - -
Short term debt 0.92M 0.19M - - -
Short long term debt - - - 8.97M 2.94M
Short long term debt total 7.02M 0.24M - - -
Other stockholder equity 1131.57M 951.35M - - -
Property plant equipment - - - - -
Total current assets 759.48M 754.21M 194.12M 147.21M 58.41M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments 709.66M 484.93M 179.41M 55.34M 0.00000M
Net receivables 0.69M 0.78M - - -
Long term debt 3.00M - - 6.53M 12.06M
Inventory 1.56M - - - -
Accounts payable 5.71M 6.52M 3.24M 0.98M 1.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.68M 0.09M 0.02M 0.03M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 32.12M 0.59M 5.18M 0.54M 0.28M
Capital lease obligations 4.02M 0.24M 0.46M 0.45M 0.12M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -223.72100M -300.76400M -121.19500M -55.35200M -0.09700M
Change to liabilities - - - - -
Total cashflows from investing activities -245.82200M -300.76400M - - -
Net borrowings 0.00000M -0.36500M - - -
Total cash from financing activities 153.59M 628.28M 87.00M 119.69M 15.45M
Change to operating activities - - - - -
Net income -160.99500M -88.03900M -48.60700M -35.44300M -12.83900M
Change in cash -224.57800M 248.80M -79.87700M 34.54M 1.70M
Begin period cash flow 257.07M 8.27M 88.14M 53.61M 51.91M
End period cash flow 32.49M 257.07M 8.27M 88.14M 53.61M
Total cash from operating activities -132.34600M -78.71300M -45.67900M -29.80400M -13.65400M
Issuance of capital stock 147.45M 629.47M 104.63M 119.53M 0.00000M
Depreciation 1.45M 0.03M 0.02M 0.01M 0.01000M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.44400M 0.00000M - - -
Change to account receivables -0.32000M -0.68900M - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 153.59M -0.82500M - - -
Change to netincome - - - - -
Capital expenditures 0.13M 0.23M 0.00000M 0.01M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 2.28M 2.91M 3.44M 4.44M -1.96700M
Stock based compensation 26.68M 11.40M 1.53M 0.68M 1.11M
Other non cash items -1.74800M -5.01400M 0.82M 0.51M 0.40M
Free cash flow -132.48000M -78.94700M -45.67900M -29.81800M -13.75100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x)
CGON
CG Oncology, Inc. Common stock		 -0.52 0.78% 65.73 - - 1501.44 7.90 1289.38
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

CG Oncology, Inc. Common stock

400 Spectrum Center Drive, Irvine, CA, United States, 92618

Key Executives

Name Title Year Born
Mr. Arthur Kuan Chairman & CEO 1991
Mr. Ambaw Bellete M.S. President & COO 1971
Dr. Vijay Kasturi M.D. Chief Medical Officer 1968
Ms. Corleen M. Roche CFO & Secretary 1967
Ms. Amy Steele Vice President of Finance, Accounting & Administration NA
Mr. Swapnil Bhargava Ph.D. Chief Technical Officer NA
Mr. Bing Kung Vice President of Corporate Development NA
Mr. Joshua F. Patterson General Counsel & Chief Compliance Officer 1976
Ms. Corleen M. Roche Chief Financial Officer 1967
Mr. Joshua F. Patterson General Counsel, Chief Compliance Officer & Secretary 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions